SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-07-06
👔
BridgeBio Oncology Therapeutics, Inc.
@BBOT_InsiderForm 4 Filing: Ben Yong Surrenders for Taxes $8,166.6 of $BBOT
TAX WITHHOLDING
⚡ MATERIALITY: 2/10
corporate issuer
BridgeBio Oncology Therapeutics, Inc.
Ticker: $BBOT
Transaction Value
$8,166.6
Price/Share: $7.80
transaction date
2026-07-01
Shares: 1,047
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Ben Yong, holds the title of Chief Med & Dev Officer at BridgeBio Oncology Therapeutics, Inc..
On 2026-07-01, the insider transacted 1,047 shares.The shares were transacted at a weighted average price of $7.80 per share, resulting in a total market-relevant value of $8,166.6.
Executive Summary Summary
Ben Yong (Chief Med & Dev Officer) had withheld for taxes $8K of $BBOT
Post-Transaction Position: 44,576 shares
SEC Accession No: 0001193125-26-296502 (CIK: 1967669)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.